company background image
GLS logo

Alivus Life Sciences NSEI:GLS Stock Report

Last Price

₹1.01k

Market Cap

₹124.2b

7D

-0.5%

1Y

57.0%

Updated

21 Dec, 2024

Data

Company Financials +

Alivus Life Sciences Limited

NSEI:GLS Stock Report

Market Cap: ₹124.2b

GLS Stock Overview

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. More details

GLS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends2/6

Rewards

Price-To-Earnings ratio (29.3x) is below the Indian market (32.4x)

Earnings are forecast to grow 23.37% per year

Trading at good value compared to peers and industry

Risk Analysis

Dividend of 2.22% is not well covered by earnings or free cash flows


My Notes

Capture your thoughts, links and company narrative

Alivus Life Sciences Limited Competitors

Aether Industries

NSEI:AETHER

₹116.2b

Granules India

BSE:532482

₹143.4b

Sanofi India

BSE:500674

₹142.2b

Procter & Gamble Health

BSE:500126

₹90.5b

Price History & Performance

Summary of share price highs, lows and changes for Alivus Life Sciences
Historical stock prices
Current Share Price₹1,013.30
52 Week High₹1,335.10
52 Week Low₹645.35
Beta0.16
1 Month Change-6.18%
3 Month Change-12.03%
1 Year Change57.02%
3 Year Change67.65%
5 Year Changen/a
Change since IPO35.38%

Recent News & Updates

Recent updates

Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 07
Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

May 10
A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Feb 15
Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Shareholder Returns

GLSIN PharmaceuticalsIN Market
7D-0.5%0.8%-4.2%
1Y57.0%39.7%19.1%

Return vs Industry: GLS exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.

Return vs Market: GLS exceeded the Indian Market which returned 19.1% over the past year.

Price Volatility

Is GLS's price volatile compared to industry and market?
GLS volatility
GLS Average Weekly Movement6.3%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.1%

Stable Share Price: GLS has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: GLS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20112,014Yasir Rawjeewww.glenmarklifesciences.com

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.

Alivus Life Sciences Limited Fundamentals Summary

How do Alivus Life Sciences's earnings and revenue compare to its market cap?
GLS fundamental statistics
Market cap₹124.16b
Earnings (TTM)₹4.24b
Revenue (TTM)₹22.05b

29.3x

P/E Ratio

5.6x

P/S Ratio

Is GLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GLS income statement (TTM)
Revenue₹22.05b
Cost of Revenue₹10.32b
Gross Profit₹11.73b
Other Expenses₹7.50b
Earnings₹4.24b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)34.56
Gross Margin53.21%
Net Profit Margin19.21%
Debt/Equity Ratio0%

How did GLS perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

0%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 21:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alivus Life Sciences Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saad ShaikhBOB Capital Markets Ltd.
Neha ManpuriaBofA Global Research
Nitin AgarwalDAM Capital Advisors